Trials / Completed
CompletedNCT00658346
Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 141 (actual)
- Sponsor
- ANRS, Emerging Infectious Diseases · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon. The natural history and treatment response is not well understood. The natural resistance to non nucleoside reverse transcriptase inhibitors and their possible low sensitivity to protease inhibitors complicate the choice of an adequate treatment options. This observational study is aimed at evaluating the antiretroviral treatment response of HIV-1 group O infected patients in comparison with HIV-1 group M infected patients. The proposed standardized follow-up will facilitate a better understanding of the natural history and treatment specificities to improve the patients management. This is a non randomized study, open label, with standardized follow-up. A total of 171 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Treatment initiation for HIV-1 group O infected patients | The first line regimen is adapted according to the hemoglobin level and the AgHBs status : * If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA) * If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA) * If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA) |
| DRUG | Treatment initiation for HIV-1 group M infected patients | The first line regimen is adapted according to the hemoglobin level and the AgHBs status : * If Hb \> 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA) * If Hb \<= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA) * If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA) |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2015-08-01
- Completion
- 2016-09-01
- First posted
- 2008-04-15
- Last updated
- 2017-01-12
Locations
2 sites across 1 country: Cameroon
Source: ClinicalTrials.gov record NCT00658346. Inclusion in this directory is not an endorsement.